<DOC>
	<DOCNO>NCT00855400</DOCNO>
	<brief_summary>The purpose clinical trial ass feasibility security intraspinal infusion autologous bone marrow stem cell treatment Amyotrophic Lateral Sclerosis patient .</brief_summary>
	<brief_title>Clinical Trial Use Autologous Bone Marrow Stem Cells Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Patients Amyotrophic Lateral Sclerosis ( ALS ) typically endure progressive paralysis due continue loss motoneuron lead death le 5 year . No treatment change natural history . Intraspinal injection bone marrow mononuclear cell ( MNC ) able ameliorate course ALS murine model , act pump trophic factor keep motoneuron functional . We design phase I/II clinical trial check feasibility approach human .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Diagnose establish follow World Federation Neurology criterion More 6 less 36 month evolution disease Medullar onset disease More 20 less 65 year old Forced Vital Capacity equal superior 50 % Total time oxygen saturation &lt; 90 % inferior 2 % sleeping time Signed informed consent Neurological psychiatric concomitant disease Need parenteral enteral nutrition percutaneous endoscopic gastrostomy nasogastric tube Concomitant systemic disease Treatment corticosteroid , immunoglobulins immunosuppressor last 12 month Inclusion clinical trial Unability understand inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Autologous</keyword>
	<keyword>Safety</keyword>
</DOC>